"Azacitidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
| Descriptor ID |
D001374
|
| MeSH Number(s) |
D02.145.150 D03.383.742.680.245.217 D13.570.685.245.217 D13.570.800.286.300
|
| Concept/Terms |
Azacitidine- Azacitidine
- 5-Azacytidine
- 5 Azacytidine
- Azacytidine
|
Below are MeSH descriptors whose meaning is more general than "Azacitidine".
Below are MeSH descriptors whose meaning is more specific than "Azacitidine".
This graph shows the total number of publications written about "Azacitidine" by people in this website by year, and whether "Azacitidine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Azacitidine" by people in Profiles.
-
Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes. Blood. 2025 Mar 13; 145(11):1126-1135.
-
Mutation- and MRD-informed treatments for transplant-ineligible patients. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):168-177.
-
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort. Blood. 2024 Nov 28; 144(22):2360-2363.
-
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood. 2024 Nov 21; 144(21):2211-2222.
-
Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clin Cancer Res. 2024 Nov 15; 30(22):5166-5179.
-
Oral decitabine-cedazuridine in acute myeloid leukaemia. Br J Haematol. 2024 Nov; 205(5):1674-1676.
-
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses. Nat Cancer. 2024 Oct; 5(10):1515-1533.
-
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. Cancer Med. 2024 Jul; 13(14):e70028.
-
Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget. 2024 Jun 03; 15:361-373.
-
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res. 2024 Jul; 142:107518.